LMTK3 review notes

2026-08-09 setup and research provenance

• The reviewed human target is LMTK3 (HGNC:19295), UniProt Q96Q04. just fetch-gene human LMTK3 supplied the current reviewed UniProt record, live QuickGO-derived GOA, and the 11-row review stub.
• Falcon deep research failed with Edison HTTP 402. The Perplexity fallback failed with HTTP 401. No provider-branded deep-research file was created or replaced with manual content. This journal therefore synthesizes the target UniProt/GOA files and the nine cached papers listed below.
• Local cache availability is important for confidence: PMID:21602804, PMID:26212333, and PMID:31310731 are abstract-only; PMID:24760852, PMID:28294115, PMID:30944027, PMID:33188023, PMID:38715938, and PMID:40405280 have cached full text. The abstract-only status limits fine-grained reinterpretation but does not undermine claims explicitly stated in those abstracts.

Exact source-annotation provenance

The live GOA input contains exactly 11 rows, all for Q96Q04. There are no duplicate normalized rows, NOT annotations, target isoforms, or annotation extensions.

• Q96Q04 appearing among the IBA supporting entities is target-self support and is not independent evidence. Mouse Lmtk1 and human LMTK2 are legitimate family evidence, while direct LMTK3 assays justify replacing the generic parent term rather than rejecting the transfer.
• The four UniProt subcellular-location mappings (membrane, Golgi membrane, axon, and dendrite) are all based on similarity to mouse Lmtk3 Q5XJV6 (Mus musculus, taxon 10090), not rat and not a direct human Q96Q04 localization assay. The target record states: [UniProtKB:Q96Q04, "Membrane {ECO:0000250|UniProtKB:Q5XJV6}"] and separately assigns axon, dendrite, and Golgi apparatus membrane with that same evidence source.

Identity, topology, transcripts, and sequence-numbering boundary

• Current UniProt describes a 1,460-aa reviewed protein whose recommended name is explicitly [UniProtKB:Q96Q04, "Serine/threonine-protein kinase LMTK3"]. The displayed signal peptide (1-20), single transmembrane helix (40-60), and kinase domain (133-411) are predicted record features; the human membrane-location statement itself is orthology-based. The large region after the kinase domain is predominantly predicted disordered sequence.
• The current record contains no ALTERNATIVE PRODUCTS block and no numbered curated UniProt isoforms. It does list two RefSeq and two Ensembl transcript/protein cross-references, with [UniProtKB:Q96Q04, "MANE-Select; ENST00000600059.6; ENSP00000472020.1; NM_001388485.1; NP_001375414.1."]. Transcript cross-references are not sufficient grounds to invent or number UniProt protein isoforms.
• PMID:33188023 used the older NP_001073903.1 sequence, which carried a 29-aa N-terminal extension absent from current Q96Q04/NP_001073903.2. Its published catalytic-domain construct 134-444 corresponds to current residues 105-415; published kinase-dead K193/D295/D313 correspond to current K164/D266/D284; and published activation-loop Y321/Y325/Y326 correspond to current Y292/Y296/Y297. Do not transfer the old coordinates unconverted. Substrate-site numbering on ERα, RCP, HSP27, and Rab7 is unaffected.

Catalytic class, structure, and the historical tyrosine name

• The historical alias "lemur tyrosine kinase 3" and older paper descriptions as an RTK are not evidence that human LMTK3 phosphorylates tyrosine substrates. The current reviewed name and catalytic reactions are serine/threonine-specific, and all well-resolved direct substrates in this cache are phosphorylated on serine.
• The structure paper solved the kinase domain at 2.1 Å and found an inactive DYG-out crystal conformation: [PMID:33188023, "Here, we solved the crystal structure of the LMTK3 catalytic domain (from now on referred as LMTK3cat) to 2.1-Å resolution using a recombinant protein comprising residues 134 to 444"]. This is a structural state, not evidence that the enzyme is inactive in cells; the same study directly measured catalysis and showed that the kinase-dead mutations abolished HSP27 phosphorylation.
• ATP use is structurally and biochemically supported. The authors concluded: [PMID:33188023, "Together, the features of the LMTK3 kinase domain indicate that the critical residues required for its binding and hydrolysis of ATP are conserved"]. GO:0005524 is therefore correct, but the phosphotransferase activity is the more informative core function.
• The paper's discussion explicitly leaves tyrosine phosphoacceptor activity unresolved: [PMID:33188023, "Since LMTK3 is predicted in silico to have dual phospho-specificity [serine/threonine (S/T) and Y], a similar approach using a Y residue as a phosphoacceptor site would add more knowledge to this topic."]. Predicted dual specificity and possible phosphorylation of activation-loop tyrosines must not be converted into an asserted LMTK3 tyrosine-kinase activity.

Catalytic substrates/sites and molecular modules

• ERα/ESR1, human breast-cancer context. The founding abstract reports direct in-vitro phosphorylation and stabilization: [PMID:21602804, "LMTK3 phosphorylated ERα, protecting it from proteasomal degradation in vitro."]. It also places LMTK3 upstream of lower PKC activity, lower AKT Ser473 phosphorylation, and increased FOXO3 recruitment to the ESR1 promoter. The cache is abstract-only, so it does not justify inventing an ERα phosphosite or a complete direct catalytic chain.
• RCP/RAB11FIP1, human cancer-cell trafficking context. In H1299/PC3 cell assays, LMTK3 loss and RCP S435A disrupted the RCP/Rab14/EphA2 trafficking module. The strongest concise result is: [PMID:28294115, "Phosphorylation of RCP at Ser435 by Lemur tyrosine kinase-3 (LMTK3) and of EphA2 at Ser897 by Akt are both necessary to promote Rab14-dependent (and Rab11-independent) trafficking of EphA2"]. RCP Ser435 is a strong human cellular LMTK3-dependent site, but this study does not supply purified LMTK3-RCP biochemical evidence. LMTK3 acts on RCP rather than EphA2 in this module; the separate metastasis validation used a KPC mouse pancreatic-cancer model.
• HSP27/HSPB1, biochemical and breast-cancer-cell context. The structure/function study mapped a basic consensus motif and directly tested full-length substrate: [PMID:33188023, "We also pinpointed Ser15 and Ser82 as the main HSP27 residues phosphorylated by LMTK3 in vitro, using site-directed mutagenesis"]. Reduced HSP27 phosphorylation after genetic or pharmacologic LMTK3 inhibition in breast-cancer cells supports an in-cell relationship, while broad SILAC phosphosite changes remain a mixture of direct and indirect targets.
• Rab7, human breast-cancer-cell/EV context. Recombinant kinase assays establish a new direct substrate: [PMID:40405280, "Our results demonstrated that LMTK3 directly phosphorylates Rab7 in vitro and that this effect is abolished following LMTK3 pharmacological inhibition"]. Non-radiolabeled assays identified Rab7 Ser72, and S72E/S72A experiments link the modification to multivesicular-body and extracellular-vesicle phenotypes in T47D and MDA-MB-231 cells.
• PPP1CA/PP1α binding, human breast-cancer-cell context. The locally cached full text supplies an auditable binding statement: [PMID:38715938, "LMTK3 consists of 1,460 amino acids with a small extracellular N-terminus, a single transmembrane domain, an adjacent catalytic domain, and large highly disordered cytoplasmic C-terminus that binds PP1"]. PMID:26212333 remains abstract-only locally; its bounded human functional statement is: [PMID:26212333, "The LMTK3/KAP1 interaction is stabilized by PP1α, which suppresses KAP1 phosphorylation specifically at LMTK3-associated chromatin regions, inducing chromatin condensation and resulting in transcriptional repression of LMTK3-bound tumor suppressor-like genes."]. A prior manual inspection of the non-cached primary PDF recorded co-immunoprecipitation, GST pull-down, and candidate docking-motif observations, but those assay-level details remain journal context rather than structured support because downstream reviewers cannot verify them from this repository. The locally auditable evidence supports PP1 binding/scaffolding, not phosphatase activity by LMTK3 or a universal assembly across cell types.
• KCC2/PP1, neuronal scaffold rather than kinase-substrate context. LMTK3 copurifies with KCC2 and recruits PP1; it is PP1 that dephosphorylates KCC2 S940. The abstract states: [PMID:38715938, "LMTK3 acts to promote the association of KCC2 with PP1 to promote the dephosphorylation of S940 within its C-terminal cytoplasmic domain, a process the diminishes KCC2 activity."]. KCC2 must not be called a direct LMTK3 phosphorylation substrate. This work provides strong evidence for a PP1-targeting scaffold function alongside kinase catalysis.

Neuronal and endocytic evidence with species boundaries

• PMID:24760852 used Lmtk3-knockout mice and cultured primary neurons from those mice. It reports: [PMID:24760852, "using cultured primary neurons from Lmtk3(-/-) mice, we found that LMTK3 is involved in the endocytic trafficking of N-methyl-d-aspartate receptors"]. The accompanying locomotor, affective-like, and striatal dopamine phenotypes are mouse organismal consequences, not direct human GO evidence.
• PMID:31310731 is also a mouse knockout study and is abstract-only. It found impaired LTP and [PMID:31310731, "abnormalities in GluA1 trafficking after AMPA stimulation in Lmtk3-KO neurons, along with a reduction in GluA1 expression in the post-synaptic density."]. This supports a neuronal endocytic/synaptic role by orthology, but not direct localization or process evidence for human Q96Q04.
• PMID:38715938 used several explicitly bounded systems: mouse brain plasma membranes, mouse knockout and acute brain slices, primary hippocampal cultures prepared from P1 mice, HEK293 interaction tests, and DIV18 rat corticohippocampal cultures for one perforated-patch arm. Its mouse-neuron imaging found: [PMID:38715938, "Both LMTK3 and KCC2 were distributed evenly and along the dendritic processes"]. Its rat boundary is explicit in Methods: [PMID:38715938, "Recordings were performed on DIV 18 rat corticohippocampal neuronal cultures at 34°C"]. These data reinforce dendritic localization and a neuronal PP1/KCC2 function, but neither organism is direct human evidence.
• The 2024 work also found that LMTK3 loss or acute inhibition increases KCC2 activity and chloride extrusion and reduces neuronal/network excitability in vitro. These are mechanistically informative neuronal roles; they remain rodent and should be secondary to the direct human catalytic/trafficking core when summarizing human Q96Q04.

Cancer-context roles: informative but bounded

• PMID:21602804 places LMTK3 in an ERα-positive breast-cancer circuit. The direct ERα phosphorylation result is molecularly important, whereas cell proliferation, xenograft size, survival association, and endocrine-response findings are disease-context consequences rather than universal core functions.
• PMID:26212333 is abstract-only in the local cache and describes a nuclear LMTK3-KAP1-PP1α scaffolding module in breast cancer. The manual full-PDF observations recorded above remain non-cached context rather than structured evidence; cached PMID:38715938 independently states that the disordered LMTK3 C-terminus binds PP1. This corroborates a PP1-linked scaffold role, but the authors' older label "oncogenic receptor tyrosine kinase" should not override direct serine/threonine enzymology.
• PMID:30944027 used human ER-positive MCF7/AC1 and CAMA-1 breast-cancer cells plus human lymphoblastoid lines. It positions LMTK3 downstream of MIR2052HG/EGR1 transcriptional regulation and reports: [PMID:30944027, "LMTK3 sustains ERα levels by reducing protein kinase C (PKC) activity, resulting in increased ESR1 transcription mediated through AKT/FOXO3 and reduced ERα degradation mediated by the PKC/MEK/ERK/RSK1 pathway."]. This supports an ERα-regulatory cancer module and aromatase-inhibitor resistance context, not a claim that every step is a direct LMTK3 substrate reaction.
• PMID:28294115 links the direct RCP Ser435 event to Rab14-dependent EphA2 trafficking, cell-cell repulsion, and dissemination. This is strong human-cell evidence for an endocytic trafficking mechanism, with the in-vivo metastasis result separately established in mice.
• PMID:33188023 adds structural enzymology, HSP27 validation, HSP90/CDC37 client biology, and inhibitor studies across cancer cells and mouse tumor models. Only the direct catalytic and structural results belong in the core molecular-function summary; antiproliferative and antitumor effects are context-dependent.
• PMID:40405280 connects direct Rab7 Ser72 phosphorylation to late-endosome/MVB handling and EV cargo in human breast-cancer cells. The authors summarize the bounded cell result as: [PMID:40405280, "LMTK3 upregulation in BC results in the formation of larger EVs with distinct protein cargo and changes to EV subpopulations, strongly suggesting a role for LMTK3 in EV biogenesis."]. Downstream monocyte/macrophage and tumor-growth effects were tested with conditioned EVs and mouse models and should remain cancer/TME-specific.

Core versus non-core synthesis and action rationale

• Primary core: ATP-dependent protein serine/threonine kinase activity. Purified-biochemical human evidence includes HSP27 Ser15/Ser82 and Rab7 Ser72; the founding study additionally reports in-vitro ERα phosphorylation. RCP/RAB11FIP1 Ser435 is a strong human cellular LMTK3-dependent site rather than a purified-enzyme result. Kinase-domain structure and kinase-dead controls exclude a mere domain prediction.
• Core cellular role: regulation of membrane/endosomal trafficking through phosphorylation of RCP and Rab7. RCP/Rab14/EphA2 and Rab7/MVB/EV results are direct in human cancer-cell systems, while mouse NMDAR/GluA1 trafficking supplies orthologous neuronal breadth.
• Secondary molecular role: PP1-targeting scaffold/adaptor activity. The cached human abstract connects PP1α to the nuclear KAP1 module, cached full text explicitly states that the LMTK3 C-terminus binds PP1, and mouse brain experiments show functional PP1 targeting to KCC2. Candidate docking-motif details remain non-cached journal context. This role should be described without asserting that LMTK3 phosphorylates KCC2 or KAP1 and without inventing a universally stable complex.
• Non-core/contextual: ATP binding; axon and dendrite localization; mouse behavioral/LTP phenotypes; ERα-positive breast-cancer proliferation and therapy response; chromatin repression; cell repulsion/metastasis; EV-driven immune-microenvironment effects. These are credible but either generic, orthology-derived, or tissue/disease bounded.
• Source-row consequences: retain the specific serine/serine-threonine kinase rows, refine generic kinase parents, replace generic protein binding with nuclear estrogen receptor binding, retain mouse-transferred membrane/Golgi statements with caveats, and keep axon/dendrite as non-core. No source row warrants removal from the evidence reviewed here.
• New annotation recommendations: add direct human late-endosome localization (GO:0005770, IDA, PMID:40405280); negative regulation of late-endosome-to-lysosome transport (GO:1902823, IMP, PMID:40405280); negative regulation of EPHA2 transport from endosome to plasma membrane (GO:1905750, IMP, PMID:28294115, has_input P29317); PP1 binding (GO:0008157, IPI, human source PMID:26212333 with additional cached support from PMID:38715938, partner P62136); and contextual positive regulation of intracellular estrogen-receptor signaling (GO:0033148, IMP, PMID:21602804). GO:0018105 was deliberately not added because current GO marks it as an obsoletion candidate; the direct RAB7A Ser72 result instead strengthens the existing protein-serine-kinase annotation and core substrate record.

Knowledge gaps and discriminating experiments

• Test purified current-sequence Q96Q04/NP_001073903.2 against matched serine, threonine, and tyrosine phosphoacceptor libraries with phospho-amino-acid analysis and current-coordinate kinase-dead controls. This would resolve whether tyrosine activity exists instead of perpetuating the historical name.
• Rebuild the PMID:33188023 structure/kinase constructs on the current 1,460-aa sequence and publish both old and current coordinates. Determine the active-state structure and which kinase or autophosphorylation event regulates current Y292/Y296/Y297.
• Establish endogenous human-cell topology and localization using validated Q96Q04 reagents. In particular, test Golgi, early/late/recycling endosomes, axons, and dendrites rather than treating mouse Q5XJV6 transfer as human IDA.
• Identify whether biologically relevant alternative human protein products exist. Current transcript cross-references should be resolved by long-read RNA sequencing and proteomics before any isoform-specific function or topology is asserted.
• Validate RCP Ser435, Rab7 Ser72, HSP27 Ser15/Ser82, and the ERα phosphorylation event side-by-side with endogenous LMTK3 knockout/rescue and catalytic-dead rescue in non-transformed as well as cancer cells. Separate direct substrates from the many indirect phosphoproteomic changes.
• Reproduce PPP1CA/PP1α binding with current-sequence Q96Q04 and systematically map the responsible docking region, then test endogenous LMTK3-PP1-KCC2 and LMTK3-PP1α-KAP1 assemblies. Determine whether scaffold function is kinase-independent and whether the docking region controls target selection beyond rodent neurons or cancer-cell chromatin.
• Use human iPSC-derived neurons to test NMDAR and GluA1 endocytic trafficking, KCC2 S940 phosphorylation/chloride extrusion, neuronal excitability, and axonal/dendritic localization. This is the clearest route from strong mouse/rat evidence to human neuronal annotation.
• Determine whether Rab7 Ser72 phosphorylation and altered EV biogenesis are physiological outside LMTK3-overexpressing breast-cancer models, and distinguish changes in EV size/cargo from EV number and from downstream immune effects.